Pay in 4 interest-free payments of $6.99 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Its molecular weight is approximately 1,419 daltons small by protein standards, which contributes to its stability profile
(Midi does not prescribe this or other unapproved peptides.) What the science says: Unlike many other popular peptides out there, AOD-9604 has fairly solid and clean safety data behind it
Published 2020 Aug 26
The US Food and Drug Administration approved this first-in-class medication for the management of type 2 diabetes (T2D) in 2022 [2], for the reduction of excess weight in adults with obesity or overweight in 2023 [3], and for moderate-to-severe obstructive sleep apnea (OSA) in people with obesity in 2024 [4]
Their advocacy for GLP1 accessibility is unmatched
When administered appropriately under professional oversight, most patients encounter minimal adverse effects while achieving desired hormonal benefits
